Bio­Marin lands $110m sale of pri­or­i­ty re­view vouch­er; Hy­bridize li­cens­es out BK virus ther­a­py

Bio­Marin an­nounced that it has sold its pri­or­i­ty re­view vouch­er for $110 mil­lion, but it hasn’t an­nounced who the buy­er is just yet.

The Cal­i­for­nia biotech won the vouch­er in No­vem­ber when it gained ap­proval for Vox­zo­go, a pre­scrip­tion med­i­cine used to in­crease lin­ear growth in chil­dren above the age of 5 with achon­dropla­sia, which im­pairs the growth of bone. This marked the third pri­or­i­ty re­view vouch­er the com­pa­ny had re­ceived, af­ter ones for Brineu­ra and Vimiz­im ap­provals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER